Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

22%

2 trials in Phase 3/4

Results Transparency

0 of 4 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1

2(25.0%)

Phase 4

2(25.0%)

N/A

2(25.0%)

Phase 2

2(25.0%)

8Total

Phase 1(2)

Phase 4(2)

N/A(2)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT07215130Recruiting

Selective Removal of Endometriotic Lesions Using CUSA Clarity in Ovarian Endometriomas

Role: lead

NCT04679831Phase 2Completed

Clinical Evaluation of Ujiplus® Against Schistosoma Mansoni

Role: collaborator

NCT02649465Phase 4Completed

SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD

Role: lead

NCT02151721Phase 1Unknown

Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer

Role: lead

NCT01709279Not ApplicableUnknown

Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure

Role: lead

NCT01062750Not ApplicableCompleted

Liver Regeneration Therapy by Intrahepatic Arterial Administration of Autologous Adipose Tissue Derived Stromal Cells

Role: lead

NCT00913289Phase 1Terminated

Liver Regeneration Therapy Using Autologous Adipose Tissue Derived Stromal Cells

Role: lead

NCT01569386Phase 2Completed

Low Intensity Physical Activity Leads to Improvement in Brachial-ankle Pulse Wave Velocity of Hemiplegics

Role: collaborator

NCT01337440Phase 4Unknown

Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases

Role: lead

All 9 trials loaded